A prospective, single-arm phase II clinical study of neoadjuvant therapy with icotinib combined with bevacizumab in EGFR-mutant positive non-small cell lung cancer.

Start Date05 Oct 2024

Sponsor / Collaborator-

CTR20241833 / Active, not recruitingNot Applicable

中国健康成年受试者在空腹状态下单次口服盐酸埃克替尼片（125mg）受试制剂（昆山龙灯瑞迪制药有限公司生产）和盐酸埃克替尼片（125mg）参比制剂（凯美纳®，贝达药业股份有限公司持证生产）的随机、开放、两制剂、两序列、四周期，完全重复交叉设计的生物等效性试验

[Translation] A randomized, open-label, two-dose, two-sequence, four-period, fully replicated crossover bioequivalence study of a single oral dose of icotinib hydrochloride tablets (125 mg) (produced by Kunshan Longdeng Redi Pharmaceutical Co., Ltd.) and a reference formulation of icotinib hydrochloride tablets (125 mg) (Conmana®, licensed production by Betta Pharmaceuticals Co., Ltd.) in healthy Chinese adult subjects in the fasting state

主要研究目的：研究空腹状态下单次口服盐酸埃克替尼片（125mg）受试制剂（昆山龙灯瑞迪制药有限公司生产）和盐酸埃克替尼片（125mg）参比制剂（凯美纳®，贝达药业股份有限公司持证生产）在健康成年受试者体内的药代动力学，评价空腹状态口服两种制剂的生物等效性。次要研究目的：评价健康受试者在空腹状态下，单次口服盐酸埃克替尼片（125mg）受试制剂和参比制剂后的安全性。

[Translation]

Primary study objective: To study the pharmacokinetics of a single oral dose of icotinib hydrochloride tablets (125 mg) (produced by Kunshan Longdeng Redi Pharmaceutical Co., Ltd.) and a reference formulation of icotinib hydrochloride tablets (125 mg) (Conmana®, licensed production by Beda Pharmaceutical Co., Ltd.) in healthy adult subjects in the fasting state, and to evaluate the bioequivalence of the two formulations in the fasting state. Secondary study objective: To evaluate the safety of a single oral dose of icotinib hydrochloride tablets (125 mg) and a reference formulation in healthy subjects in the fasting state.

Start Date20 Jul 2024

Sponsor / Collaborator

Kunshan Rotam Reddy Pharmaceutical Co. Ltd.

NCT06517953 / RecruitingPhase 2IIT

A Phase II Study to Assess Befotertinib and Icotinib as First-Line Treatment in Patients With Locally Advanced or Metastatic NSCLC and Uncommon EGFR Mutation(IcomBine, GASTO-10114)

This research study aims to explore the combination of two targeted drugs as first-line treatment for Non-Small Cell Lung Cancer (NSCLC) with uncommon EGFR mutation.

Start Date17 Jul 2024

Sponsor / Collaborator

Sun Yat-Sen University

100 Clinical Results associated with Icotinib Hydrochloride

100 Translational Medicine associated with Icotinib Hydrochloride

100 Patents (Medical) associated with Icotinib Hydrochloride

384

Literatures (Medical) associated with Icotinib Hydrochloride

01 Dec 2024·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Simultaneous determination of icotinib, osimertinib, aumolertinib, and anlotinib in human plasma for therapeutic drug monitoring by UPLC-MS/MS

Article

Author: Gao, Jinglin ; Zhao, Haopeng ; Xu, Yuxiang ; Wang, Mingxia ; Gao, Xiaonan ; Bai, Jing ; Qie, Hongxin ; Feng, Zhangying

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as icotinib, osimertinib, and aumolertinib have emerged as promising treatment options for EGFR mutated Non-small cell lung cancer (NSCLC) patients. Additionally, anlotinib, an anti-angiogenic agent targeting VEGFR, FGFR, and PDGFR, has been used in combination with EGFR-TKIs in NSCLC cases. A method utilizing ultrahigh performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was developed and validated for quantifying icotinib, osimertinib, aumolertinib and anlotinib simultaneously in clinical TDM. The chromatographic separation was performed using a Kinetex C18 column (100 mm × 2.1 mm) and an elution gradient of ammonium acetate in water acidified with 0.1 % formic acid and in acetonitrile. The assay was validated over a linear range of 4-2000 ng/mL for icotinib, 2-1000 ng/mL for osimertinib, 1-500 ng/mL for aumolertinib, and 0.8-400 ng/mL for anlotinib, following the guidelines on bioanalytical methods by FDA. The quantification method exhibited satisfactory performance in terms of selectivity, accuracy (from 91.3 % to 107 %), precision (intra- and inter-day coeffficients of variation ranged from 0.944 % to 7.48 %), linearity, recovery (from 86.0 % to 91.9 %), matrix effect (IS-normalized matrix factors were from 96.7 % to 102 %), and stability. Overall, the method proved to be sensitive, reliable, and straightforward, enabling successful simultaneous determination of blood concentrations of icotinib, osimertinib, aumolertinib, and anlotinib in patients. The validity of the method has been confirmed across various instruments.

01 Nov 2024·BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Design and activity evaluation of new EGFR tyrosine kinase inhibitors containing cyclic polyamines

Article

Author: Zuo, Jun-Fang ; Chen, Guoliang ; Li, Chao ; Zhang, Yan-Hong ; Cheng, Yi ; Guo, Liang-Liang

The EGFR-TK pathway is pivotal in non-small-cell lung cancer (NSCLC) treatment, drugs targeting both EGFR wild-type and mutant tumor cells are still urgently needed. The focus of our study is on ATP-competitive inhibitors crucial for NSCLC therapy, specifically targeting the epidermal growth factor receptor (EGFR). A series of derivatives of Erlotinib and Icotinib were developed by incorporating a macrocyclic polyamine into a quinazoline scaffold to enhance their inhibitory activity against drug-resistant cells. The compounds exhibit modest activity against EGFR triple mutants (EGFR^del¹⁹^/T790M/C797S). Compound b demonstrated slightly improved inhibition activity against PC-9^d^{el19/T790M/C797S} (IC₅₀ = 496.3 nM). This could provide some insights for optimizing EGFR inhibitors, particularly in the context of EGFR triple mutants.

01 Aug 2024·BMJ Open

Cost-effectiveness of adjuvant icotinib versus chemotherapy for patients with stage II–IIIA EGFR-mutated non-small cell lung cancer in China

Article

Objective:

Icotinib has been approved for adjuvant treatment of stage II–IIIA non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutations in China, yet the long-term costs and outcomes of this strategy are unknown. Thus, we examined the cost effectiveness of adjuvant icotinib, compared with adjuvant chemotherapy, for the treatment of resected stage II–IIIA EGFR-mutated NSCLC.

Design:

We performed a cost-effectiveness analysis from the perspective of the Chinese healthcare system, comparing 2-year adjuvant icotinib with four cycles of adjuvant chemotherapy. Costs and quality-adjusted life years (QALYs) were estimated using a Markov model. Model inputs were obtained from local data and literature. The influence of model parameters and assumptions was explored in sensitivity analyses. All costs are expressed in 2022 US dollars, and costs and QALYs were discounted at a rate of 5% per year. The willingness-to-pay (WTP) threshold was set at three times the per capita gross domestic product.

Setting:

The Chinese healthcare system perspective.

Participants:

A hypothetical Chinese cohort of patients with resected stage II–IIIA EGFR-mutated NSCLC.

Interventions:

Icotinib versus chemotherapy.

Primary outcome measure:

Costs, QALYs, incremental cost-effectiveness ratio.

Results:

The incremental cost per QALY gained with the use of 2-year icotinib, from the Chinese healthcare system perspective, was $3440.66 compared with adjuvant chemotherapy. At a WTP threshold of $40 500, adjuvant icotinib was the optimal treatment in over 99% of replications. The interpretation of the results was insensitive to model and input assumptions.

Conclusions:

Compared with adjuvant chemotherapy, adjuvant icotinib may be a cost-effective treatment for resected stage II–IIIA EGFR-mutated NSCLC as the WTP threshold is set at $40 500 per QALY.

News (Medical) associated with Icotinib Hydrochloride

30 May 2023

·www.globenewswire.com

C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC

C4 Therapeutics to Receive a $10 Million Upfront Payment, a $25 Million Equity Investment and is Eligible to Receive up to $357 Million for Development and Commercial Milestones Plus Royalties on Net Sales in Greater China Betta Pharmaceuticals to Develop and Commercialize CFT8919 in Greater China and Eligible to Receive Royalties on Net Sales Outside of Greater China The Exclusive Licensing Agreement with Betta Pharmaceuticals Accelerates Development of CFT8919 in Key International Markets WATERTOWN, Mass. and HANGZHOU, China, May 30, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, and Betta Pharmaceuticals Co. Ltd (Betta) (SZ300558), a leading pharmaceutical company focusing on the development of innovative oncology therapies in China, today announced an exclusive licensing agreement for the development and commercialization of CFT8919 in Greater China (including Hong Kong SAR, Macau SAR and Taiwan). CFT8919 is an orally bioavailable BiDAC™ degrader designed to be potent and selective against EGFR L858R for non-small cell lung cancer (NSCLC) patients. Under the terms of the agreement, C4T expects to receive $35 million, which includes $10 million in upfront cash as well as a $25 million one-time equity investment, to be completed following the receipt of required regulatory approvals and other customary closing conditions. Additionally, C4T is eligible for up to $357 million in potential milestones and low to mid-double-digit percent royalties on net sales in the licensed territories. Betta will be responsible for the development, manufacturing and commercialization of CFT8919 in the licensed territories and is eligible to receive low single-digit percent royalties on net sales outside of Greater China. C4T retains the right to develop and commercialize CFT8919 in all territories outside of Greater China. “We are excited to partner with Betta to develop CFT8919, an orally bioavailable allosteric EGFR L858R degrader, with the potential to treat NSCLC patients with EGFR L858R mutations in Greater China and beyond,” said Andrew Hirsch, president and chief executive officer of C4 Therapeutics. “With their strong track record of developing and commercializing NSCLC therapies in China, we believe Betta is the ideal partner to advance CFT8919 clinical development in a region where there is a high prevalence of lung cancer patients with the EGFR L858R mutation.” “The collaboration with C4T is another important collaboration for Betta’s partnerships with top-tier biotech companies,” said Lieming Ding, chairman and chief executive officer of Betta. “The collaboration will further expand Betta’s product pipeline and improve the productivity of the company's R&D, from discovery to clinical development, and to commercialization. We will leverage the capabilities and resources of both parties and continue developing innovative drugs to benefit more patients.” In preclinical studies, CFT8919 is active in in vitro and in vivo models of EGFR L858R driven NSCLC with broad coverage of on-target resistant mutations and intracranial activity, with the potential to prevent or treat brain metastases in these patients. CFT8919 has been designed to bind to an allosteric site, which is uniquely created by the L858R activating mutation, allowing for exquisite selectivity for this mutation. Further, CFT8919 was designed to be effective independent of secondary EGFR mutations, for example T790M and/or C797S. Additionally, CFT8919 demonstrated potent anti-proliferation activity against a panel of cell lines harboring either L858R single mutation or L858R with additional EGFR mutations that confer resistance to approved EGFR inhibitors such as osimertinib or erlotinib, while sparing cell lines with wild-type EGFR. In China, approximately 693,000 patients were diagnosed with NSCLC in 2020 and approximately 40% of these cases are driven by the EGFR mutation. The L858R mutation is the second most common EGFR mutation, found in approximately 40% of NSCLC patients with EGFR mutations in China. Typically, these patients experience a less durable response to approved EGFR inhibitors, including osimertinib. C4T is on track to submit an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) for CFT8919 for the treatment of NSCLC in the first half of 2023. MSQ Ventures served as an advisor to C4T and Goodwin Procter LLP served as legal counsel to C4T. Han Kun Law Offices served as legal counsel to Betta. About CFT8919CFT8919 is an orally bioavailable allosteric BiDAC™ degrader that is designed to be potent and selective against EGFR bearing an oncogenic L858R mutation. In preclinical studies, CFT8919 is active in in vitro and in vivo models of L858R driven non-small cell lung cancer. Importantly, CFT8919 retains full activity against additional EGFR mutations that confer resistance against approved EGFR inhibitors including L858R-C797S, L858R-T790M, and L858R-T790M-C797S. About C4 TherapeuticsC4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines that harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. C4T is advancing multiple targeted oncology programs to the clinic and expanding its research platform to deliver the next wave of medicines for difficult-to-treat diseases. For more information, please visit www.c4therapeutics.com. About Betta PharmaceuticalsBetta Pharmaceuticals Co., Ltd. (SZ300558) is a commercial-staged pharmaceutical company dedicated to the development of innovative oncology products to meet high unmet medical needs. With about 2,000 employees in Hangzhou and Beijing, Betta's integrated R&D platform ranges from small-molecule to biologics discovery, clinical development, manufacturing, sales and marketing. Betta's leading product – icotinib (Conmana®), the first innovative oncology product domestically developed and launched in China – is one of the top selling targeted therapies for patients with non-small cell lung cancer, having achieved more than 13 billion RMB accumulated sales since launched and benefited more than 500,000 patients in China. Betta currently has 3 marketed products, 15 programs in clinical development and 2 molecules under NDA review by the NMPA. Throughout the years, Betta has set up strategic partnerships with Xcovery LLC., Merus N.V., Agenus Inc. and other top-tier biotech companies, with the ultimate objective to deliver innovative health solutions around the world. For more information, please visit http://www.bettapharma.com/en.php. Forward-Looking StatementsThis press release contains “forward-looking statements” of C4 Therapeutics, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, express or implied statements regarding our ability to develop potential therapies for patients; the design and potential efficacy of our therapeutic approaches; the predictive capability of our TORPEDO® platform in the development of novel, selective, orally bioavailable BiDAC™ and MonoDAC™ degraders; the potential timing, design and advancement of our preclinical studies and clinical trials, including the potential timing for and receipt of regulatory authorization related to clinical trials and other clinical development activities including clinical trial commencement; our ability and the potential to successfully manufacture and supply our product candidates for clinical trials; our ability to replicate results achieved in our preclinical studies or clinical trials in any future studies or trials; regulatory developments in the United States and foreign countries; our ability to fund our future operations; our ability to realize development and commercialization milestones and receive royalties on the commercial sale of our product candidates; our ability to realize the anticipated benefits of this collaboration; and our ability to complete the contemplated sale of equity securities. Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the initiation, timing, advancement and conduct of preclinical and clinical studies and other development requirements for our product candidates; the risk that any one or more of our product candidates will cost more to develop or may not be successfully developed and commercialized; and the risk that the results of preclinical studies and/or clinical trials will or will not be predictive of results in connection with future studies or trials. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in C4 Therapeutics’ most recent Annual Report on Form 10-K and/or Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and C4 Therapeutics undertakes no duty to update this information unless required by law. C4T Contacts:Investors: Courtney SolbergSenior Manager, Investor RelationsCSolberg@c4therapeutics.com Media: Loraine Spreen Director, Corporate Communications & Patient Advocacy LSpreen@c4therapeutics.com Betta Pharmaceuticals Contact:Jianhao Shen Director, Securities AffairsJianhao.shen@bettapharma.com

License out/in

30 Jul 2021

·endpts.com

Shooting straight for Venclexta, a seasoned Chinese CEO has global dreams for his startup

As one of the founding execs and longtime chief medical officer at Betta Pharma, Fenlai Tan isn’t just well aware of the allure of a me-better strategy in China. He helped create it. Over the past 11 years, the biotech — which took its name for the vocal resemblance to “better” — had accrued a whopping $9.2 billion valuation (RMB$60 billion) thanks to a single drug: icotinib, a first-generation EGFR inhibitor that became China’s first approved targeted therapy after proving just as effective as AstraZeneca’s Iressa in a head-to-head trial, and safer for Chinese patients. Tan’s new ambitions, though, go even further. Now in the CEO seat, he’s landed $35 million in a pre-B round for Guangzhou Lupeng Pharma, the startup he co-founded with Yi Chen. Instead of first-in-China, they will be gunning for global premier status with a slate of small molecule drugs that they believe would be attractive even in the eyes of multinational drugmakers. Lupeng is among a new generation of startups eager to do more than becoming a bridge for Western drugs into China or fast follower — both strategies that have been successfully adopted but, some would argue, might be overheated. “A lot of times it probably is not me-better, it’s me-worse probably,” Tan told Endpoints News. “If you look at like PD-1, there’s like 180-something — over 70-something PD-1s already went to the clinical stage. How come? It’s not possible, you know, we’ll have 70 of this kind of PD-1 inhibitors on the market.” Meanwhile more established players, from Junshi to I-Mab to Tan’s old colleagues at Jacobio, have shown it’s possible for homegrown drugs to shine on the international stage, with their respective deals for Covid-19 and CD47 antibodies. For Lupeng, the pitch right now is centered around a lead drug targeting BCL-2, which is being tested in patients in China, the US, the UK and Spain. Tan sees the drug as a “real competitor” to AbbVie and Roche’s Venclexta, which was the first and remains the only BCL-2 inhibitor on the market. Chen, a medicinal chemist by training who’s based in San Francisco, is leading the discovery effort while Tan brings the clinical expertise to coordinate global trials. Lupeng now employs 62 staffers, including a handful executing on clinical development in the US. Two more blood cancer drugs are in the clinic, and he expects two more programs — one for hepatitis B and one for multiple sclerosis — to follow suit soon. Singapore’s Temasek led the round, which is likely to be the second to last before an IPO. Lake Bleu Capital, Lilly Asia Ventures and Fontus Capital also invested.

AntibodySmall molecular drugIPO

100 Deals associated with Icotinib Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
-	Icotinib Hydrochloride	L01XE48	DB11737

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Non-Small Cell Lung Cancer	CN	Betta Pharmaceuticals Co., Ltd.	07 Jun 2011

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Lung Cancer with Brain Metastasis	Phase 3	CN	Betta Pharmaceuticals Co., Ltd.	20 Jul 2018
Adenocarcinoma	Phase 3	CN	Betta Pharmaceuticals Co., Ltd.	01 Sep 2014
EGFR Mutation Lung Cancer	Phase 3	CN	Betta Pharmaceuticals Co., Ltd.	01 Sep 2014
EGFR positive non-small cell lung cancer	Phase 3	CN	Betta Pharmaceuticals Co., Ltd.	01 Sep 2014
Advanced Lung Adenocarcinoma	Phase 3	CN	Betta Pharmaceuticals Co., Ltd.	01 Dec 2012
EGFR positive Adenocarcinoma of Lung	Phase 3	CN	Betta Pharmaceuticals Co., Ltd.	01 Dec 2012
Non-small cell lung cancer stage IIIB	Phase 2	CN	Betta Pharmaceuticals Co., Ltd.	09 May 2018
progressive non-small cell lung cancer	Phase 2	CN	Betta Pharmaceuticals Co., Ltd.	01 Jan 2018
Psoriasis	Phase 2	CN	Betta Pharmaceuticals Co., Ltd.	29 Nov 2017
Lung Cancer	Phase 2	CN	Betta Pharmaceuticals Co., Ltd.	18 Nov 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ChiCTR1800016948 \| NCT05104788 (NEOIPOWER, WCLC2024) Manual	Phase 2	EGFR positive Adenocarcinoma of Lung Neoadjuvant EGFR Mutation	133	Chemotherapy	ejosbmwkng(qzzqrimlpe) = eijhkctbts hpxdwzismt (hbgnibvcvn )	Positive	09 Sep 2024
				First-generation EGFR-TKIs	ejosbmwkng(qzzqrimlpe) = dacvfjfvpg hpxdwzismt (hbgnibvcvn )
NCT01996098 (ICTAN, GASTO1002, ASCO2024) Manual	Phase 3	EGFR-mutated non-small Cell Lung Cancer Adjuvant EGFR Mutation	251	Icotinib 12 months	gkqggtvtcs(ayozpffuvc) = fjtbbaasrs yfdynxgiml (dzjfuzhhef, 43.3 - 80.3) View more	Positive	24 May 2024
				Icotinib 6 months	gkqggtvtcs(ayozpffuvc) = jjfwvnkvdq yfdynxgiml (dzjfuzhhef, 44.8 - 81.6) View more
WCLC2023 Manual	Phase 1/2	EGFR-mutated non-small Cell Lung Cancer First line EGFR Mutation	24	Aumolertinib+Icotinib	uswwcgyfxj(qutfgfhncx) = aumolertinib 110 mg po qd plus icotinib 125mg po tid ccyuhmojhj (myaxabgesn ) View more	Positive	11 Sep 2023
NCT01929200 (ICOMPARE study, Pubmed)	Phase 2	EGFR positive Adenocarcinoma of Lung Adjuvant	109	1-year icotinib	plevygvfoz(gtpbxaizmu) = chdzkiowzs vjmbsihinc (axhmiwcwqs, 26.6 - 44.8)	Positive	20 Jun 2023
				2-year icotinib	plevygvfoz(gtpbxaizmu) = sohipwcrje vjmbsihinc (axhmiwcwqs, 33.1 - 70.1)
NCT02264210 (GASTO1003, CORIN, Pubmed)	Phase 2	EGFR-mutated non-small Cell Lung Cancer Adjuvant	128	Adjuvant icotinib	jflxptteid(waeddqirkq) = zwzqahrxqw hbxljkbvth (wyzgkjigzd, 91.3 - 99.9)	Positive	01 Mar 2023
				icotinib (Observation)	jflxptteid(waeddqirkq) = ymbyljswwi hbxljkbvth (wyzgkjigzd, 75.1 - 92.9)
ESMO_ASIA2022	Not Applicable	Advanced Lung Adenocarcinoma First line	105	icotinib	bhguogswxn(cxuoxmpipa) = hzicldjpwd vqgncayutk (jinhjkagka )	-	03 Dec 2022
				icotinib plus vinorelbineicotinib plus vinorelbine	bhguogswxn(cxuoxmpipa) = djklwufhob vqgncayutk (jinhjkagka )
NCT02934256 (Pubmed) Manual	Phase 2	Acoustic Neuroma \| Neurofibromatosis 2	10	icotinib	krybbzjtcf(hlqnvmdken) = -23.58% and -22.01% iqdnhkmajr (ghbknoapli ) View more	Positive	21 Oct 2022
CSCO2022	Not Applicable	EGFR positive Adenocarcinoma of Lung	40	盐酸埃克替尼加量	wegddfdugr(bukoxcuyzp) = plwskvivge eqvvoddphi (wuqobjuutu ) View more	-	21 Sep 2022
NCT03346811 (CHALLENGE, Pubmed) Manual	Phase 2	EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma EGFR Mutation-Positive	116	Icotinib	wrhmzznxtd(fmxgtmxwqr) = aycisyofjq ejximdkacg (occxflepdk, 43.1 - 61.9) View more	Positive	21 Jul 2022
NCT02044328 (ICAPE, AACR2022) Manual	Phase 2	EGFR-mutated non-small Cell Lung Cancer Adjuvant EGFR Mutation	79	Icotinib 125 mg	evemjgmpag(ghyyjgaaxo) = hyssropeik paisalusov (vfkstrwais, 33.6 - 51.8) View more	Positive	15 Jun 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis